

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*

Rennova Health, Inc.

(Name of Issuer)

Common Stock, \$.01 par value

(Title of Class of Securities)

759757 10 7

(CUSIP Number)

Seamus Lagan
400 South Australian Avenue, 8th Floor
West Palm Beach, FL 33401
(561) 855-1626

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 2, 2016

(Date of Event which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box .

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosure provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1. Names of Reporting Persons Seamus Lagan	
2. Check the Appropriate Box if a Member of a Group	
	(a) <input type="checkbox"/>
	(b) <input type="checkbox"/>
3. SEC Use Only	
4. Source of Funds (See Instructions) OO	
5. Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) <input type="checkbox"/>	
6. Citizenship Or Place Of Organization Ireland	
Number Of Shares Beneficially Owned By Each Reporting Person With	7. Sole Voting Power 2,000,000
	8. Shared Voting Power 421,927
	9. Sole Dispositive Power 2,000,000
	10. Shared Dispositive Power 421,927
11. Aggregate Amount Beneficially Owned by Each Reporting Person 2,421,927	
12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) <input checked="" type="checkbox"/>	
13. Percent of Class Represented by Amount in Row (11) 14.4%	
14. Type of Reporting Person IN	

1. Names of Reporting Persons
Alcimedede LLC

2. Check the Appropriate Box if a Member of a Group (a)
(b)

3. SEC Use Only

4. Source of Funds (See Instructions)
OO

5. Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

6. Citizenship Or Place Of Organization
Delaware

Number Of Shares Beneficially Owned By Each Reporting Person With	7.	Sole Voting Power -0-	
	8.	Shared Voting Power 421,927	
	9.	Sole Dispositive Power -0-	
	10.	Shared Dispositive Power 421,927	

11. Aggregate Amount Beneficially Owned by Each Reporting Person
421,927

12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

13. Percent of Class Represented by Amount in Row (11)
2.9%

14. Type of Reporting Person
OO

1. Names of Reporting Persons
Epizon Ltd.

2. Check the Appropriate Box if a Member of a Group (a)
(b)

3. SEC Use Only

4. Source of Funds (See Instructions)
OO

5. Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

6. Citizenship Or Place Of Organization
Commonwealth of the Bahamas

	7.	Sole Voting Power	
Number Of Shares Beneficially Owned By Each Reporting Person With	-0-		
	8.	Shared Voting Power	
		1,884,334	
	9.	Sole Dispositive Power	
		-0-	
	10.	Shared Dispositive Power	
		1,884,334	

11. Aggregate Amount Beneficially Owned by Each Reporting Person
1,884,334

12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

13. Percent of Class Represented by Amount in Row (11)
12.7%

14. Type of Reporting Person
OO

1. Names of Reporting Persons
P. Wilhelm F. Toothe, Trustee of The Shanoven Trust

2. Check the Appropriate Box if a Member of a Group

(a)
(b)

3. SEC Use Only

4. Source of Funds (See Instructions)
OO

5. Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

6. Citizenship Or Place Of Organization
Commonwealth of the Bahamas

Number Of Shares Beneficially Owned By Each Reporting Person With	7.	Sole Voting Power -0-	
	8.	Shared Voting Power 1,884,334	
	9.	Sole Dispositive Power -0-	
	10.	Shared Dispositive Power 1,884,334	

11. Aggregate Amount Beneficially Owned by Each Reporting Person
1,884,334

12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

13. Percent of Class Represented by Amount in Row (11)
12.7%

14. Type of Reporting Person
OO

Names of Reporting Persons	
1.	The Shanoven Trust
2.	Check the Appropriate Box if a Member of a Group
	(a) <input type="checkbox"/>
	(b) <input type="checkbox"/>
3.	SEC Use Only
4.	Source of Funds (See Instructions)
	OO
5.	Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) <input type="checkbox"/>
6.	Citizenship Or Place Of Organization
	Commonwealth of the Bahamas
Number Of Shares Beneficially Owned By Each Reporting Person With	7. Sole Voting Power
	-0-
	8. Shared Voting Power
	1,884,334
	9. Sole Dispositive Power
	-0-
	10. Shared Dispositive Power
	1,884,334
11.	Aggregate Amount Beneficially Owned by Each Reporting Person
	1,884,334
12.	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) <input checked="" type="checkbox"/>
13.	Percent of Class Represented by Amount in Row (11)
	12.7%
14.	Type of Reporting Person
	OO

Item 1. Security and Issuer

This Amendment No. 1 to Schedule 13D amends the Statement on Schedule 13D, dated November 2, 2015, with respect to the Common Stock, \$0.01 par value per share (the "Shares"), of Rennova Health, Inc., a Delaware corporation (the "Issuer"), filed by Seamus Lagan, Alcimedede LLC, a Delaware limited liability company ("Alcimedede"), Epizon Ltd. ("Epizon"), a Bahamian international business corporation, which is wholly-owned by The Shanoven Trust, of which P. Wilhelm F. Toothe serves as the trustee; P. Wilhelm F. Toothe, as trustee of The Shanoven Trust; and The Shanoven Trust. Except as expressly amended below, Schedule 13D, dated November 2, 2015 remains in effect.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 is hereby amended to include the following:

This Amendment No. 1 to Schedule 13D is being filed to report the grant to Mr. Lagan on May 2, 2016 of an aggregate 2,000,000 options to purchase a like number of Shares of the Issuer. With respect to such options, 1,000,000 options are currently exercisable through December 31, 2017, at an exercise price of \$5.00 per Share, and 1,000,000 options are currently exercisable through December 31, 2022, at an exercise price of \$10.00 per Share.

Item 5. Interest in Securities of the Issuer

Item 5 is hereby amended to include the following:

As of May 2, 2016, Mr. Lagan may be deemed to beneficially own 2,421,927 Shares (or approximately 14.4% of the total number of Shares currently outstanding), which consists of 2,000,000 stock options owned of record by Mr. Lagan, as described in Item 3. above, and as to which Mr. Lagan may be deemed to have sole dispositive and voting power, and 421,927 Shares owned of record by Alcimedede. Mr. Lagan may be deemed to have shared dispositive and voting power with Alcimedede over the 421,927 Shares owned of record by Alcimedede. Such Shares do not include 1,884,334 Shares owned of record by Epizon (or approximately 12.7% of the total number of Shares currently outstanding), and with respect to such Shares, The Shanoven Trust, P. Wilhelm F. Toothe, as trustee of The Shanoven Trust, and Epizon share dispositive and voting power; and 1,000 shares of the Issuer's Series B Convertible Preferred Stock, owned of record by Epizon. Such Shares also do not include Shares owned by a third party entity, and which third party entity is owned by a trust of which P. Wilhelm F. Toothe serves as trustee.

Item 7. Materials to be Filed as Exhibits

Item 7 is hereby amended to include the following:

Exhibit B – Joint Filing Agreement pursuant to Rule 13d-1(k).

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

May 20, 2016

/s/ Seamus Lagan
Seamus Lagan, individually

May 20, 2016

Alcimedede LLC
By: /s/ Seamus Lagan
Seamus Lagan, Sole Manager

May 20, 2016

Epizon Ltd.
By: The Shanoven Trust

By: /s/ P. Wilhelm F. Toothe
P. Wilhelm F. Toothe, Trustee

May 20, 2016

The Shanoven Trust

By: /s/ P. Wilhelm F. Toothe
P. Wilhelm F. Toothe, Trustee

Exhibit B**JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)**

The undersigned acknowledge and agree that the foregoing statement on Amendment No. 1 to Schedule 13D is filed on behalf of each of the undersigned. The undersigned acknowledge that each shall be responsible for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent it knows or has reason to believe that such information is inaccurate. This Joint Filing Agreement may be executed in any number of counterparts and all of such counterparts taken together shall constitute one and the same instrument.

Dated: May 20, 2016

/s/ Seamus Lagan
Seamus Lagan, Individually

Alcimedede LLC

By: /s/ Seamus Lagan
Seamus Lagan, Sole Manager

Epizon Ltd.

By: The Shanoven Trust

By: /s/ P. Wilhelm F. Toothe
P. Wilhelm F. Toothe, Trustee

The Shanoven Trust

By: /s/ P. Wilhelm F. Toothe
P. Wilhelm F. Toothe, Trustee